Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Other Operating Expenses (2024 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Other Operating Expenses for 2 consecutive years, with $870.6 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 75.13% to $870.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $902.3 million through Dec 2025, up 178.85% year-over-year, with the annual reading at $56.1 million for FY2025, 800.82% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $870.6 million at Madrigal Pharmaceuticals, up from $18.1 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $870.6 million in Q4 2025, with the low at -$174.2 million in Q3 2024.